Streamlining EHR Integration through Common Data Models for RWE

Electronic Health Records (EHRs) provide a vast source of real-world data (RWD), but differences in formats and terminologies across systems create integration challenges. Common Data Models (CDMs) offer a solution by providing standardized data structures that enable consistent analysis across institutions, regions, and platforms.

This guide explores how pharmaceutical professionals and clinical trial stakeholders can use CDMs to harmonize EHR data, facilitating reliable real-world evidence (RWE) generation for regulatory and scientific purposes.

Why Common Data Models Are Essential:

Inconsistent EHR formats across healthcare systems hinder large-scale observational studies. CDMs solve this problem by:

• Defining standard tables and fields (e.g., patient demographics, diagnoses, drug exposures)
• Ensuring uniform terminologies (e.g., SNOMED CT, LOINC, RxNorm)
• Enabling cross-database analytics with common logic
• Supporting reproducible research through aligned metadata

Whether working on safety studies or comparative effectiveness research, CDMs improve data quality and integrity, enhancing GMP compliance when observational results are used to support regulatory filings.

Key Common Data Models Used in EHR Integration:

Here are the most widely adopted CDMs in the pharma and research community:

1. OMOP (Observational Medical Outcomes Partnership):
   • Developed by the Observational Health Data Sciences and Informatics (OHDSI) collaborative
   • Captures clinical data in a person-centric format
   • Supports standardized vocabularies and cohort definitions
2. Sentinel Common Data Model:
   • Created by the U.S. FDA’s Sentinel Initiative
   • Focused on post-marketing safety surveillance
   • Includes robust privacy protections and distributed analytics
3. PCORnet CDM:
   • Developed by the Patient-Centered Outcomes Research Institute
   • Optimized for patient-centered outcomes and engagement studies
4. HL7 FHIR (Fast Healthcare Interoperability Resources):
   • Not a CDM in the traditional sense, but a data exchange standard
   • Enables real-time EHR integration via APIs
   • Increasingly used in dynamic RWE platforms

Steps to Implement a Common Data Model for EHR Integration:

To adopt a CDM in your real-world evidence program, follow these steps:

1. Choose a CDM: Based on study goals, regulatory alignment, and partner ecosystem.
2. Extract Data: From source EHRs in both structured and unstructured formats.
3. Transform and Map: Clean and normalize data using extract-transform-load (ETL) pipelines, aligning with the CDM structure.
4. Standardize Terminologies: Use tools like Usagi for OMOP to map local codes to global standards.
5. Validate Data Quality: Perform checks on completeness, consistency, and referential integrity.
6. Deploy Analytics Tools: Utilize cohort builders, statistical engines, and visualization dashboards compatible with the CDM.

For long-term success, integrate CDM workflows into your Pharma SOP templates for reproducibility and compliance.

Regulatory Acceptance of CDM-Based Evidence:

Global regulatory bodies increasingly recognize CDM-aligned evidence in submissions. For example:

• The USFDA accepts Sentinel CDM results in drug safety monitoring.
• The EMA leverages OMOP-standardized data in DARWIN EU for RWE analysis.
• Health Canada encourages structured data submissions to improve review efficiency.

Maintaining traceability from original EHR sources to CDM tables is critical for regulatory audits. Align with data provenance principles to ensure integrity.

Common Challenges and Solutions in CDM Adoption:

• Challenge: Mapping diverse data sources with incompatible formats
• Solution: Use ETL automation tools like WhiteRabbit and RabbitInAHat (OMOP) for structured mapping
• Challenge: Clinical terminologies vary by institution or country
• Solution: Leverage SNOMED CT crosswalks and LOINC/RxNorm mappings
• Challenge: Governance and access across multi-site collaborations
• Solution: Employ federated data models or distributed queries with privacy controls

Build competency by including CDM mapping training in your Pharma Validation programs to improve internal capacity.

Case Example: OMOP CDM in Oncology RWE

In an oncology real-world evidence study, a pharmaceutical sponsor mapped EHR data from five hospitals to the OMOP CDM. They used standardized definitions to:

• Identify eligible lung cancer patients
• Track treatment regimens and outcomes
• Evaluate progression-free survival across treatment cohorts

This enabled fast data extraction and consistent outcome definitions, accelerating the generation of real-world insights aligned with StabilityStudies.in protocols.

Best Practices for Long-Term Sustainability:

• Document your ETL pipelines and update them regularly as source EHRs evolve
• Use open-source CDM tools to avoid vendor lock-in
• Join communities like OHDSI or PCORnet to stay updated on CDM advancements
• Align with pharma regulatory compliance for traceable and auditable CDM processes
• Incorporate metadata standards to improve data discoverability and reusability

CDM maturity models are emerging to guide institutions through phased adoption. Early wins in pilot projects can build momentum for wider rollouts.

Conclusion: Building RWE Infrastructure through CDMs

As the demand for high-quality real-world evidence grows, integrating EHRs using common data models becomes indispensable. CDMs provide the structure, standardization, and scalability needed to transform raw EHR data into regulatory-grade evidence.

Whether leveraging OMOP, Sentinel, PCORnet, or HL7 FHIR, success lies in methodical implementation, rigorous validation, and strategic alignment with regulatory and scientific goals. With the right approach, CDMs can unlock the full potential of EHRs for next-generation evidence generation in pharmaceuticals.

How to Use Electronic Health Records (EHRs) to Generate Real-World Evidence

Electronic Health Records (EHRs) have transformed how clinical data is captured, stored, and utilized in healthcare. For the pharmaceutical industry, EHRs offer a powerful resource to extract real-world evidence (RWE), enabling better decision-making, safety monitoring, and post-market surveillance. But using EHRs for research requires a deep understanding of data quality, integration protocols, and regulatory compliance.

This tutorial outlines a step-by-step approach to using EHR data in pharma studies to generate RWE, including study planning, data sourcing, and ethics approval — aligned with pharma regulatory requirements.

Understanding the Value of EHRs in RWE Generation:

Unlike controlled clinical trials, EHRs capture patient data in real-world clinical settings. This includes information on patient demographics, diagnoses, procedures, lab results, medications, comorbidities, and healthcare utilization.

• Reflects actual patient care settings
• Enables retrospective and longitudinal studies
• Supports rare disease research and outcomes analysis
• Improves trial design and feasibility assessment

By leveraging EHRs, pharma companies can complement randomized controlled trials (RCTs) with more diverse and generalizable evidence.

Step-by-Step Guide to Using EHRs for Real-World Research:

Step 1: Define Your Study Objectives and Population

Start with a clear research question and target population. Define inclusion/exclusion criteria using EHR-representable parameters such as ICD-10 codes, lab values, or medication lists.

Step 2: Identify Suitable EHR Data Sources

• Hospital-based EHR systems (e.g., Epic, Cerner)
• Integrated Delivery Networks (IDNs)
• National health data networks
• Claims-EHR linked databases
• Research platforms like PCORnet, OHDSI, or TriNetX

Make sure the data source covers your population and has sufficient follow-up duration.

Step 3: Ensure Data Access and Legal Compliance

Obtain data use agreements (DUAs), IRB approvals, and confirm HIPAA compliance. If using de-identified or limited datasets, ensure they follow the Safe Harbor method or expert determination rules.

For international datasets, verify compliance with GDPR or local data protection regulations.

EHR Data Extraction and Curation Techniques:

EHR data is often messy and incomplete. It is essential to curate data before using it in RWE studies.

1. Extract: Pull structured (e.g., demographics, labs) and unstructured (e.g., clinical notes) data.
2. Transform: Map diagnosis/procedure codes (ICD-10, SNOMED, LOINC) into a common data model.
3. Clean: Address missing values, outliers, or implausible records.
4. Link: Combine data from multiple sources (EHR + claims or registries).

Platforms like OMOP CDM standardize these tasks for global pharma research.

Handling Structured and Unstructured Data in EHRs:

Structured EHR data includes diagnosis codes, lab values, vital signs, etc. Unstructured data includes physician notes, radiology reports, and discharge summaries.

Use Natural Language Processing (NLP) tools to extract key variables from unstructured data. Combine both data types for improved RWE accuracy and completeness.

Ensure that pharmaceutical SOP guidelines are followed when working with NLP algorithms or machine-learning techniques for data extraction.

Ethical and Regulatory Considerations in EHR-Based Research:

EHR data often includes sensitive personal health information (PHI). To remain compliant:

• Get IRB or ethics committee approval, even for de-identified data
• Implement data encryption and access controls
• Use secure servers and data audit trails
• Train staff on GCP and data privacy standards

According to CDSCO and GMP guidelines, all data handling must be traceable and auditable.

Study Designs That Work Well with EHR Data:

• Retrospective Cohort Studies: Identify exposure and track outcomes over time.
• Case-Control Studies: Match cases and controls using demographic or clinical variables.
• Nested Case-Control: Use cohort data for efficient rare outcome studies.
• Cross-sectional Analysis: Evaluate prevalence or current treatment patterns.

These designs can be enhanced with real-time patient registries or longitudinal data sources available in EHRs.

Benefits and Limitations of EHR Data in Pharma Studies:

Advantages:

• Rich longitudinal clinical data
• Scalable access to large patient populations
• Reduced need for patient re-contact
• Supports predictive analytics and machine learning

Limitations:

• Data fragmentation across healthcare systems
• Variable data quality and missingness
• Inconsistent coding and documentation practices
• Complex de-identification and linkage processes

Work with data scientists and biostatisticians to mitigate these challenges. Standardize procedures with validation protocols for EHR-derived datasets.

Ensuring Data Quality and Validation:

Before using EHR data for submission or regulatory insights, ensure that quality metrics are in place:

• Completeness and accuracy checks
• Validation against external registries or benchmarks
• Consistency across data elements
• Timeliness and relevance of captured data

Use logic rules and medical coding algorithms to verify extracted datasets.

Checklist for Pharma Teams Using EHRs in RWE Studies:

• Define study objectives and eligibility using EHR variables
• Secure ethical approvals and DUAs
• Extract and clean structured/unstructured data
• Map data to standardized coding systems
• Conduct quality assurance and validation
• Maintain data security and audit trails
• Report findings using real-world contexts

Conclusion: A Roadmap to Reliable RWE via EHRs

EHRs offer a powerful and scalable solution to generate high-quality real-world evidence. From feasibility studies to long-term safety tracking, they unlock new research possibilities that go beyond traditional clinical trials. However, navigating EHR data complexity, privacy laws, and ethical boundaries is critical for successful implementation.

By following this structured approach and aligning with industry expectations on pharmaceutical stability testing, pharma professionals can confidently integrate EHRs into their RWE strategy and enhance the impact of their research on real-world patient outcomes.